blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP0452074

EP0452074 - Ergoline-8-carboxamides for blocking 5HT receptors [Right-click to bookmark this link]
Former [1991/42]Improvements in and relating to ergoline-8-carboxamides
[1996/04]
StatusNo opposition filed within time limit
Status updated on  29.11.1996
Database last updated on 14.09.2024
Most recent event   Tooltip29.11.1996No opposition filed within time limitpublished on 15.01.1997 [1997/03]
Applicant(s)For all designated states
ELI LILLY AND COMPANY
Lilly Corporate Center
Indianapolis, IN 46285 / US
[N/P]
Former [1991/42]For all designated states
ELI LILLY AND COMPANY
Lilly Corporate Center
Indianapolis, Indiana 46285 / US
Inventor(s)01 / Cohen, Marlene Lois
10532 Coppergate
Carmel, Indiana 46032 / US
02 / Robertson, David Wayne
4290 Hunters Ridge Lane
Greenwood, Indiana 46142 / US
[1991/42]
Representative(s)Tapping, Kenneth George, et al
Lilly Industries Limited European Patent Operations Erl Wood Manor Windlesham
Surrey GU20 6PH / GB
[N/P]
Former [1991/42]Tapping, Kenneth George, et al
Lilly Industries Limited European Patent Operations Erl Wood Manor
Windlesham Surrey GU20 6PH / GB
Application number, filing date91303088.809.04.1991
[1991/42]
Priority number, dateUS1990050832411.04.1990         Original published format: US 508324
[1991/42]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP0452074
Date:16.10.1991
Language:EN
[1991/42]
Type: A3 Search report 
No.:EP0452074
Date:04.03.1992
Language:EN
[1992/10]
Type: B1 Patent specification 
No.:EP0452074
Date:24.01.1996
[1996/04]
Search report(s)(Supplementary) European search report - dispatched on:EP16.01.1992
ClassificationIPC:C07D457/06, A61K31/48
[1991/42]
CPC:
C07D457/06 (EP,US); C07D471/06 (KR); A61P13/02 (EP);
A61P15/00 (EP); A61P25/04 (EP); A61P25/18 (EP);
A61P25/20 (EP); A61P25/24 (EP); A61P25/26 (EP);
A61P43/00 (EP); A61P7/02 (EP); A61P9/08 (EP);
A61P9/10 (EP); A61P9/12 (EP); H02J7/00 (KR) (-)
Designated contracting statesAT,   BE,   CH,   DE,   DK,   ES,   FR,   GB,   GR,   IT,   LI,   LU,   NL,   SE [1991/42]
TitleGerman:Ergolin-8-carboxamide zum Blockieren von 5HT-Rezeptoren[1996/04]
English:Ergoline-8-carboxamides for blocking 5HT receptors[1996/04]
French:Ergoline-8-carboxamides pour bloquer les récepteurs de la 5HT[1996/04]
Former [1991/42]Verbesserungen bezüglich Ergolin-8-carboxamide
Former [1991/42]Improvements in and relating to ergoline-8-carboxamides
Former [1991/42]Améliorations concernant des ergoline-8-carboxamides
Examination procedure17.04.1991Examination requested  [1991/42]
28.11.1994Despatch of a communication from the examining division (Time limit: M06)
05.04.1995Reply to a communication from the examining division
10.05.1995Despatch of communication of intention to grant (Approval: Yes)
31.07.1995Communication of intention to grant the patent
29.09.1995Fee for grant paid
29.09.1995Fee for publishing/printing paid
Opposition(s)25.10.1996No opposition filed within time limit [1997/03]
Fees paidRenewal fee
25.03.1993Renewal fee patent year 03
14.04.1994Renewal fee patent year 04
07.04.1995Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]US2997470  (PIOCH RICHARD P);
 [XD]EP0296748  (LILLY CO ELI [US])
 [A]  - JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, no. 2, February 1990, WASHINGTON, US; pages 652 - 656; J.W.MISNER ET AL.: '(8BETA)-6-METHYLERGOLINE AMIDE DERIVATIVES AS SEROTONIN ANTAGONISTS: N1-SUBSTITUENT EFFECTS ON VASCULAR 5HT2 RECEPTOR ACTIVITY.'
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.